TapImmune Inc. Announces Issuance of US Patent

Patent with broad claims relates to Method of Enhancing an Immune Response by augmenting the levels of TAP Seattle, WA, October 27 , 2011 — TapImmune Inc. (OTCBB: TPIV) announced that the US Patent Office has issued Patent 7,994,146 entitled “Method of Enhancing an Immune Response”. The invention relates to a method of enhancing an…

Details

TapImmune Inc. Announces Issuance of US Patent

Patent with broad claims relates to Method of Enhancing an Immune Response by augmenting the levels of TAP Seattle, WA, October 27 , 2011 — TapImmune Inc. (OTCBB: TPIV) announced that the US Patent Office has issued Patent 7,994,146 entitled “Method of Enhancing an Immune Response”. The invention relates to a method of enhancing an…

Details

TapImmune to Present at BIT’s 2nd Annual World Congress on Immunodiseases and Therapy in Guangzhou, China, November 18, 2011

Analysis of data showing relationship between TAP levels, disease progression and therapeutic intervention to be discussed SEATTLE, WA TapImmune Inc. (OTCBB: TPIV), a biotechnology company developing immunotherapies, today announced that its Chairman and CEO, Dr. Glynn Wilson, is an invited speaker at BIT’s 2nd Annual World Congress on Immunodiseases and Therapy to be held in…

Details

TapImmune to Sponsor Phase 1 Breast Cancer Vaccine Trial Following Recent FDA Approval of Investigational New Drug Application

SEATTLE, WA & Rochester, Minn. TapImmune Inc. (OTCBB: TPIV), a leading biotechnology company developing immunotherapies, today announced that following FDA IND approval, it will sponsor a Phase I HER-2/neu targeted therapeutic vaccine trial in HER-2/neu positive breast cancer patients at the Mayo Clinic. The trial stems from a technology license option and sponsored research agreements…

Details

TapImmune Inc to Present at Aegis Capital Emerging Growth Conference in Las Vegas on April 30 2011

SEATTLE, WA TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutics and vaccines in the areas of oncology and infectious disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will present at the Aegis Capital Emerging Growth Conference on Saturday, April 30. The conference will take place between April 28…

Details

TapImmune Provides Corporate Update

Seattle WA, TapImmune Inc. (OTCBB: TPIV), is pleased to provide this corporate update to our current and future shareholders and other interested parties. Our collaborative development programs for a breast cancer vaccine and for a new generation of smallpox vaccines are proceeding on schedule. We anticipate that an IND for the first Phase I study…

Details

TapImmune Inc. Featured in the March 11 Issue of the Financial Hub, www.cpreports.com

SEATTLE (GLOBE NEWSWIRE) — The article (http://www.cpreports.com/?p=931), written by respected business writer Gene Marcial, provides insights into recent progress of TapImmune Inc. (OTCBB:TPIV), its research and development collaborations and the status of the Company’s product portfolio. The article also discusses the current market cap and potential market cap of the Company and predicts the Company’s…

Details

Status of Clinical Development Clarification

Seattle WA, TapImmune Inc. (OTCBB: TPIV), wishes to provide a clarification to the Press Release issued on March 1, 2011 ‘TapImmune Closes $1.16 Million Funding’ We mistakenly stated in the footnote ‘About TapImmune’ section that “TapImmune is in clinical development of a vaccine technology to treat HER-2/neu positive breast cancer”. Our statement should have read…

Details